Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is thought to affect 1780000 patients in USA and Europe. Its incidence is increasing rapidly in Asia. Drugs with proven clinical activity that are currently used in UC patients include salicylates, steroids, azathioprine and infliximab. None of them is active in every patient and all carry significant side effects. There is a need for other active drugs in UC. Low dose methotrexate has been used for decades in psoriasis, rheumatoid arthritis and Crohn's disease. In these diseases, it is an active, well tolerated and cheap drug. In UC there have been several open series, most of which are retrospective. Overall, these studies have shown promising results, with response rates of 50 to 72 %. There have been two randomized clinical trials of methotrexate vs. placebo in UC. Both were negative but methotrexate was prescribed orally at suboptimal doses. So far, there is no evidence for the efficacy of methotrexate in UC. Therefore, there is a need for clinical trials with methotrexate using adequate dosage and the parenteral route. Two multicenter randomized trials of methotrexate 25 mg/week parenterally vs. placebo are either ongoing (METEOR, the European trial) or being built up (MERIT, the US trial). These trials should determine if methotrexate is a valuable therapeutic option in UC.
Keywords: Ulcerative Colitis, Methotrexate, therapy, Immunomodulators, Cyclosporine, Azathioprine, Rheumatoid Arthritis, GETAID, ECCO
Current Drug Targets
Title: Methotrexate: A Drug of the Future in Ulcerative Colitis?
Volume: 12 Issue: 10
Author(s): Franck Carbonnel
Affiliation:
Keywords: Ulcerative Colitis, Methotrexate, therapy, Immunomodulators, Cyclosporine, Azathioprine, Rheumatoid Arthritis, GETAID, ECCO
Abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is thought to affect 1780000 patients in USA and Europe. Its incidence is increasing rapidly in Asia. Drugs with proven clinical activity that are currently used in UC patients include salicylates, steroids, azathioprine and infliximab. None of them is active in every patient and all carry significant side effects. There is a need for other active drugs in UC. Low dose methotrexate has been used for decades in psoriasis, rheumatoid arthritis and Crohn's disease. In these diseases, it is an active, well tolerated and cheap drug. In UC there have been several open series, most of which are retrospective. Overall, these studies have shown promising results, with response rates of 50 to 72 %. There have been two randomized clinical trials of methotrexate vs. placebo in UC. Both were negative but methotrexate was prescribed orally at suboptimal doses. So far, there is no evidence for the efficacy of methotrexate in UC. Therefore, there is a need for clinical trials with methotrexate using adequate dosage and the parenteral route. Two multicenter randomized trials of methotrexate 25 mg/week parenterally vs. placebo are either ongoing (METEOR, the European trial) or being built up (MERIT, the US trial). These trials should determine if methotrexate is a valuable therapeutic option in UC.
Export Options
About this article
Cite this article as:
Carbonnel Franck, Methotrexate: A Drug of the Future in Ulcerative Colitis?, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818252
DOI https://dx.doi.org/10.2174/138945011796818252 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Potential Use of Dietary Natural Products, Especially Polyphenols, for Improving Type-1 Allergic Symptoms
Current Pharmaceutical Design Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2
Current Drug Research Reviews Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response
Current Molecular Pharmacology Structural Biology of Recombinant Bovine Pancreatic Phospholipase A2 and its Inhibitor Complexes
Current Topics in Medicinal Chemistry Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ADAM-Integrin Interactions: Potential Integrin Regulated Ectodomain Shedding Activity
Current Pharmaceutical Design Periarticular Corticosteroid Treatment of the Sacroiliac Joint
Current Rheumatology Reviews Ectopic Lymphoid Neogenesis and Lymphoid Chemokines in Sjogren’s Syndrome: At the Interplay between Chronic Inflammation, Autoimmunity and Lymphomagenesis
Current Pharmaceutical Biotechnology Rhinocerebral Mucormycosis with Orosinusal Involvement: Diagnostic and Surgical Treatment Guidelines
Endocrine, Metabolic & Immune Disorders - Drug Targets Preparation and Evaluation of Chitosan Loaded Naproxen Nanoparticles by Emulsion Interfacial Reaction Method
Drug Delivery Letters Are Patient Self-Report Questionnaires as "Scientific" as Biomarkers in "Treat-totarget" and Prognosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Nanotherapeutics for the Treatment of Cancer and Arthritis
Current Drug Metabolism Macrophage Activation Syndrome in Childhood Rheumatic Diseases
Current Rheumatology Reviews In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics